Obr Peer-spectives
Adjuvant Lung Cancer – Roy Herbst, MD and Robert Figlin, MD discuss the recent ASCO20 plenary presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in the adjuvant setting for NSCLC EGFR+ patients
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:00
- Mas informaciones
Informações:
Sinopsis
Roy Herbst, MD and Robert Figlin, MD discuss the implications of the recent ASCO20 presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in Stage I-III EGFR+ NSCLC patients